Solving pain through innovation
Grünenthal are committed to transforming lives through cutting edge science.
We are building on our core expertise in pain through the Pain Innovation Unit, an initiative that aims to deliver solutions through patient-inspired R&D, adding high value to patients and Grünenthal.
"Our Pain Innovation Unit is committed to finding better pain solutions through patient-driven research and we are proud to have the aspiration to solve pain. This can only be achieved through a collaborative approach and we want to work with patients, clinicians and researchers to better understand the mechanisms behind pain diseases enabling the development of more effective treatments."
The Pain Innovation Unit consists of four sections:
Select an area of focus for more information
Our translational science and intelligence group aims to unravel the mechanisms behind diseases.
We have used our extensive knowledge across pain indications to:
- Develop our proprietary PainSpectrum to link current targets to disease
- Target specific unmet need within niche pain areas
- Explore new pathways for target identification within the area of pain and build foundations to develop disease-modifying agents.
Learn more about Our Approach to disease understanding.
Our patient engagement and clinical science group nurtures links with patient organisations and contributes to clinical development of medical products.
Patients are at the heart of our R&D strategy. We engage with patients at every step, including mapping patient journeys, developing patient-reported outcomes, and providing patient samples.
Here also lies the responsibility for leading the clinical science through robust trial methodology, novel endpoints, and understanding regulator, payor, physician and patient needs.
Our new chemical entity research group works tirelessly to develop new medical products than can change patients’ lives for the better.
We build on our extensive experience in NCE research with proprietary chemistry to invent valuable chemical matter. Our treatments are developed with both symptomatic as well as disease-modifying potential.
Our external innovation and opportunities group drives collaboration in science.
We drive external innovation to add to our existing treatment portfolio and enter into new modalities (e.g. biologics). We are leading the science through collaboration (e.g. 23andMe) and building networks (e.g. human tissue network) to further scientific breakthroughs.